Skip to main navigation

Investor Navigation

Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials
- SEC Filings
Governance
IR Resources

Press Releases

Year

10 Jul '2026

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06 Jul '2026

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

15 Jun '2026

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

09 Jun '2026

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

27 May '2026

Context Therapeutics to Present at the Jefferies Global Healthcare Conference

18 May '2026

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

06 May '2026

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

02 Apr '2026

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

23 Mar '2026

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

19 Mar '2026

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12

Investor Tools

Print Page
RSS Feeds
Search

Request Email Alerts

© 2026 Context Therapeutics Inc. All rights reserved.